Neuren Pharmaceuticals (ASX:NEU) said its partner, Nasdaq-listed Acadia Pharmaceuticals, secured marketing authorization from Health Canada for its Daybue drug developed to treat Rett syndrome in adult and pediatric patients aged two and older, according to a Thursday filing with the Australian Securities Exchange.
Rett syndrome is a genetic neurological disorder causing progressive motor skills and language loss.
The approval was the first received outside the US, said Neuren Chief Executive Jon Pilcher.
Neuren Pharmaceuticals shares rose more than 2% in morning trade on Thursday.
Price (AUD): $12.99, Change: $+0.29, Percent Change: +2.28%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。